WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS

The DDDs are based on the treatment of hypercholesterolemia.


C10A LIPID MODIFYING AGENTS, PLAIN

Pantethine, which is also used in the treatment of hyperlipidemi, is classified as a vitamin in A11HA.


C10AA HMG CoA reductase inhibitors

This group comprises agents which act as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase).
Atorvastatin in combination with amlodipine is classified in C10BX03.

C10AB Fibrates

Clofibrate and analogues are classified here.

The DDD for fenofibrate is based on the micronised formulation.

C10AC Bile acid sequestrants

This group comprises substances (such as colestyramine and colestipol) which reduces the cholesterol level by increasing the excretion of bile acid.

C10AD Nicotinic acid and derivatives

This group comprises high strength preparations (e.g. nicotinic acid tab 500 mg) used as cholesterol reducers. Nicotinic acid or derivatives in low strength preparations (e.g. nicotinic acid tab 50 mg) are classified in C04A - Peripheral vasodilators.

Combinations of nicotinic acid and laropiprant are classified in C10AD52.

C10AX Other lipid modifying agents

This group comprises all cholesterol and triglyceride reducers, which cannot be classified in the preceding groups.

Sulodexide is classified in B01AB.

The DDD for evolocumab is based on dosing every second week.

Last updated: 2018-12-13